Products - Arthritis | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 85 products

Date | Title

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2019
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 January 2016
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Anakinra for treating Still’s disease (TA685)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
AposHealth for knee osteoarthritis (MTG76)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
11 April 2023
Apremilast for treating active psoriatic arthritis (TA433)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Apremilast for treating juvenile psoriatic arthritis in people 5 to 17 years [TSID12089]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Arthrosamid for symptomatic treatment of knee osteoarthritis
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 August 2007
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis (IPG110)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2005
Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis (IPG111)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2005
Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 August 2017
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2024
Bimekizumab for treating active psoriatic arthritis (TA916)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2023
Bimekizumab for treating ankylosing spondylitis [TSID10334]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bimekizumab for treating axial spondyloarthritis (TA918)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2023
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Deucravacitinib for treating active psoriatic arthritis [TSID11981]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
16 January 2026
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Filgotinib for Axial spondyloarthritis [ID6594]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
FLEXISEQ for osteoarthritis (MIB80)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
14 September 2016
GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
3 April 2024
Genicular artery embolisation for pain from knee osteoarthritis (IPG708)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 October 2021
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Golimumab for the treatment of psoriatic arthritis (TA220)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2011
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2011
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 January 2018
Gout: diagnosis and management (NG219)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 June 2022
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis (IPG512)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2015
Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee (IPG317)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 September 2009
Insertion of a synthetic cartilage for first CMC osteoarthritis
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Ixekizumab for treating axial spondyloarthritis (TA718)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Joint distraction for ankle osteoarthritis (IPG538)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2015
Joint distraction for knee osteoarthritis without alignment correction (IPG529)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 July 2015
Lateral elbow resurfacing for arthritis (IPG705)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 September 2021
Magnetic resonance therapy for knee osteoarthritis (IPG702)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 August 2021
Metatarsophalangeal joint replacement of the hallux (IPG140)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2005
Midcarpal hemiarthroplasty for wrist arthritis (IPG663)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 October 2019
Osteoarthritis in over 16s (QS87)
Product type:
Quality standard
Last updated:
19 October 2022
Published:
11 June 2015
Osteoarthritis in over 16s: diagnosis and management (NG226)
Product type:
Guidance
Programme:
NICE guideline
Published:
19 October 2022
Platelet-rich plasma injections for knee osteoarthritis (IPG637)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2019
Radiofrequency denervation for OA shoulder pain
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Radiofrequency denervation for osteoarthritic knee pain (IPG767)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 June 2023
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Product type:
Advice
Programme:
Evidence summary
Published:
21 July 2020
Rheumatoid arthritis in adults: management (NG100)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
12 October 2020
Published:
11 July 2018
Rheumatoid arthritis in over 16s (QS33)
Product type:
Quality standard
Last updated:
9 January 2020
Published:
28 June 2013
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2017
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Shoulder resurfacing arthroplasty (IPG354)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2010
Spondyloarthritis (QS170)
Product type:
Quality standard
Published:
28 June 2018
Spondyloarthritis in over 16s: diagnosis and management (NG65)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 June 2017
Published:
28 February 2017
Sternoclavicular joint replacement for arthritis
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis (IPG726)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 May 2022
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (IPG727)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
1 June 2022
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
10 July 2019
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2016
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Tofacitinib for treating active ankylosing spondylitis (TA920)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (IPG595)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
8 November 2017
Total hip arthroplasty using the superpath approach for osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Total wrist replacement (IPG271)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 August 2008
Upadacitinib for treating active ankylosing spondylitis (TA829)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 September 2022
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 November 2021
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 December 2020
Ustekinumab for treating active psoriatic arthritis (TA340)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
4 June 2015